Biotech Industry · global
Novartis licenses Abogen mRNA therapy for $575 million upfront, targeting autoimmune diseases
Enabling cells in the body to produce therapeutic molecules that engage T cells is the approach ABO2203 seeks to establish. The cross-border licensing deal also includes options on other RNA programs, but the potential total of nearly $7.8 billion depends on subsequent development and commercial outcomes.
Beyond delivering instructions for making vaccines, mRNA may also enable the body to produce molecules that treat autoimmune diseases. A new agreement between Novartis and Chinese biotech company Abogen commits resources to this approach: using an mRNA-encoded T-cell engager to attempt to eliminate B cells and move toward more durable disease control.
Abogen announced on October 2 that the agreement covers an exclusive global license for investigational therapy candidate ABO2203, as well as exclusive licensing options for other RNA platform programs. The upfront payment is $575 million; Reuters and Dow Jones Newswires also confirmed the deal’s key terms. However, the transaction remains subject to necessary regulatory approvals and other closing conditions.
ABO2203 is designed to target both CD19 on B cells and CD3 on T cells, linking the two types of immune cells to direct T cells to eliminate B cells. Its distinguishing feature is the use of mRNA to instruct cells within the body to produce the engager. Abogen hopes this will achieve a B-cell “reset,” but clinical data are still needed to determine whether it can deliver durable efficacy and what advantages it may offer over conventional recombinant protein engagers.
Novartis told Reuters that Abogen’s RNA technology could complement its existing strategy for treating autoimmune diseases. This also illustrates that the agreement’s value rests on more than a single drug candidate: options on other programs give Novartis room to secure additional licenses as the platform produces more therapies.
The deal’s financial terms need to be understood in layers. According to Abogen’s announcement, additional payments could total approximately $7.2 billion only if options for all programs are exercised and agreed development, regulatory and commercial milestones are met. Including the upfront payment, the potential total is approximately $7.775 billion, with possible additional royalties on product sales; this is not an amount paid in full at closing. Reuters cited a fund manager who holds Novartis shares as assessing that the relatively small upfront payment helps improve the deal’s risk profile.
For patients, the license brings development resources, while evidence of efficacy still needs to accumulate. Abogen said ABO2203 has entered clinical evaluation for autoimmune diseases, but this announcement did not provide patient numbers, trial results for specific diseases or complete safety data. Whether it can maintain acceptable safety while eliminating B cells, and how long disease control can last, will determine how far this therapy produced within the body can progress.